TrialBMC medicine2022

Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.

Yue Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.